Boceprevir and telaprevir: new treatments for chronic hepatitis C

Citations Over Time

Abstract

Abstract Boceprevir and telaprevir are new antiviral drugs indicated for the treatment of chronic hepatitis C genotype 1 infection. In our New products review, Steve Chaplin presents the clinical data relating to their efficacy and adverse effects and Professor Geoffrey Dusheiko discusses their place in treatment.

Related Papers

• → Boceprevir and telaprevir: new treatments for chronic hepatitis C(2012)1 cited
• → Cost-effectiveness of direct-acting antivirals for chronic hepatitis C(2013)1 cited
• → DGI-061 Safety of Triple Treatment in Chronic Hepatitis C(2013)
• → P-62 Molecular evolutionary classification of hepatitis C virus based on phylogenetic trees and genetic distance(1995)
• Hepatitis C virus control: viral resistance, new therapeutic targets and host defense(2016)